These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19745589)

  • 21. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
    Murphy CG; Seidman AD
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S58-65. PubMed ID: 19596644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of breast cancer resistance to anthracyclines or taxanes: an overview of the proposed roles of noncoding RNA.
    Li XJ; Zha QB; Ren ZJ; Tang JH; Yao YF
    Curr Opin Oncol; 2015 Nov; 27(6):457-65. PubMed ID: 26371779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug transporters in breast cancer: response to anthracyclines and taxanes.
    Kümler I; Stenvang J; Moreira J; Brünner N; Nielsen DL
    Expert Rev Anticancer Ther; 2015; 15(9):1075-92. PubMed ID: 26313418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of docetaxel for breast cancer.
    Lwin Z; Leighl N
    Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant anthracyclines: time for a change of heart?
    O'Regan R
    Oncology (Williston Park); 2011 Feb; 25(2):140, 142. PubMed ID: 21456385
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiotoxicities of breast cancer treatment.
    Viale PH; Yamamoto DS
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594
    [No Abstract]   [Full Text] [Related]  

  • 27. [Predictive factors for response to chemotherapy in breast cancers].
    Miyoshi Y; Noguchi S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():154-9. PubMed ID: 17682152
    [No Abstract]   [Full Text] [Related]  

  • 28. "To the heart of the matter...".
    Kamen BA; Drachtman R
    Pediatr Hematol Oncol; 2000; 17(1):5-7. PubMed ID: 10689709
    [No Abstract]   [Full Text] [Related]  

  • 29. The alphabet soup of chemotherapy.
    Dinman S
    Plast Surg Nurs; 2007; 27(3):173-5. PubMed ID: 17901830
    [No Abstract]   [Full Text] [Related]  

  • 30. Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer.
    Schmitt M; Sweep FC
    Eur J Cancer; 2009 Sep; 45(14):2444-6. PubMed ID: 19647994
    [No Abstract]   [Full Text] [Related]  

  • 31. The best use of chemotherapy in the adjuvant setting.
    Cardoso F; Piccart MJ
    Breast; 2003 Dec; 12(6):522-8. PubMed ID: 14659130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal.
    Mouridsen HT
    Recent Results Cancer Res; 1996; 140():191-9. PubMed ID: 8787062
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    Russo A; Autelitano M; Bisanti L
    J Natl Cancer Inst; 2006 Dec; 98(24):1826-7. PubMed ID: 17179484
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.
    Anders CK; Peppercorn J
    Cancer Invest; 2009 Jan; 27(1):13-6. PubMed ID: 19160108
    [No Abstract]   [Full Text] [Related]  

  • 35. Anthracyclines.
    Hamilton D; Batist G
    Cancer Chemother Biol Response Modif; 2005; 22():19-33. PubMed ID: 16110606
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in chemotherapy options for metastatic breast cancer: introduction of epothilones.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):29-30. PubMed ID: 17824553
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore.
    de Lima Lopes G; Chien R; Hornberger J
    Breast J; 2013; 19(2):220-1. PubMed ID: 23320386
    [No Abstract]   [Full Text] [Related]  

  • 38. [[How to finance chemotherapy with new cancer drugs?].
    Livartowski A; Beuzeboc P; Le Vu B; Courbard M; Pierga JY; Extra JM; Scholl S; Pouillart P
    Bull Cancer; 2000 Oct; 87(10):745-54. PubMed ID: 11084538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.
    Hangai S; Iwase S; Kawaguchi T; Kogure Y; Miyaji T; Matsunaga T; Nagumo Y; Yamaguchi T
    J Altern Complement Med; 2013 Nov; 19(11):905-10. PubMed ID: 23829813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant trastuzumab for breast cancer: the other side of the coin.
    Gopalakrishnan S; Linnane J
    BMJ; 2005 Nov; 331(7526):1202-3. PubMed ID: 16293846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.